Vertex Pharmaceuticals (VRTX) revenue

Revenue · fiscal 2025
$12.00B

Vertex Pharmaceuticals (VRTX) reported revenue of $12.00B in fiscal 2025 (the year ended December 31, 2025). That is 8.9% higher than the $11.02B of fiscal 2024. Figures as of 18 Nov 2026, 07:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$12.00B
Change on fiscal 2024
+8.9%
Growth, 5 years
+14.1% a year
Growth, 10 years
+27.8% a year
Highest on record
$12.00Bfiscal 2025
Lowest on record
$101.89Mfiscal 2009
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Vertex Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 14.1% a year; over ten years the rate was 27.8% a year. Across the 18 fiscal years on record (2008–2025), the highest was $12.00B in fiscal 2025 and the lowest $101.89M in fiscal 2009.

History · 18 fiscal years

Revenue by fiscal year

Vertex Pharmaceuticals revenue, year by year

Vertex Pharmaceuticals (VRTX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$12.00B 8.9% up
2024$11.02B 11.7% up
2023$9.87B 10.5% up
2022$8.93B 17.9% up
2021$7.57B 22.1% up
2020$6.21B 49.1% up
2019$4.16B 36.6% up
2018$3.05B 22.5% up
2017$2.49B 46.2% up
2016$1.70B 64.9% up
2015$1.03B 77.9% up
2014$580.42M 52.1% down
2013$1.21B 20.6% down
2012$1.53B 8.3% up
2011$1.41B 883.9% up
2010$143.37M 40.7% up
2009$101.89M 41.9% down
2008$175.50M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Vertex Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
Pfizer PFE$62.58B2025
Danaher DHR$24.57B2025
Intuitive Surgical ISRG$10.06B2025
Vertex Pharmaceuticals VRTX$12.00B2025
Medtronic MDT$36.36B2026
Bristol-Myers Squibb BMY$48.20B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on VRTX

Vertex Pharmaceuticals, figure by figure

Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value

Vertex Pharmaceuticals revenue: questions and answers

What is Vertex Pharmaceuticals's revenue?

Vertex Pharmaceuticals (VRTX) reported revenue of $12.00B in fiscal 2025 (the year ended December 31, 2025). That is 8.9% higher than the $11.02B of fiscal 2024.

What is the growth rate of Vertex Pharmaceuticals's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 14.1% a year; over ten years the rate was 27.8% a year.

What are the highest and lowest revenue figures on record for Vertex Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was $12.00B in fiscal 2025 and the lowest $101.89M in fiscal 2009.

How is Vertex Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.